Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $169.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: 4121.12%
• EPS Growth: 83.30%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 87,405,310
• 10 Day Avg. Volume: 1,954,645
• 30 Day Avg. Volume: 1,333,579
• PEG Ratio: 0.02
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 12.06
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: -0.26
• Enterprise Value/Revenue: -0.39
• Enterprise Value/Gross Profit: -0.42
• Enterprise Value/Ebitda: 3.15
• 1Y Price Target: $4.30
• Price Target Upside: 142.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $2.00 ▲(12.99% Upside)

The score is mainly constrained by weak financial performance driven by persistent, deep negative operating and free cash flow and ongoing losses. Technicals are supportive with strong momentum versus moving averages, but very overbought RSI/Stoch readings temper the outlook. Corporate events add a positive offset via strengthened financing and pipeline progress, while valuation remains challenging due to negative earnings and no dividend support.

Positive Factors

Liquidity Strengthening Financing

An oversubscribed $135M private placement materially improves near- to medium-term liquidity, funding IND-enabling work and early clinical milestones. This reduces immediate external funding pressure, allowing execution on development programs and de-risking timelines through late-2027 milestones.

Proprietary iPSC Platform & Pipeline Breadth

Century’s Allo-Evasion iPSC platform and multiple programs across oncology, autoimmune and T1D create a durable strategic advantage. A platform enabling off-the-shelf cell therapies can scale faster than autologous approaches, diversify clinical risk, and support sustained long-term value if clinical proof emerges.

Board Strength & Capital Formation Experience

Adding directors with life-science investing and capital formation expertise enhances governance and strategic oversight. That experience is sustainable value: improved access to sophisticated investors, stronger fundraising execution, and better alignment of R&D prioritization with investor expectations over multiple financing cycles.

Negative Factors

Persistent Negative Cash Flow

Deeply negative operating and free cash flow indicate structural cash burn tied to R&D. Sustained negative cash generation forces reliance on external financing, constrains strategic optionality, and can compel program prioritization or partnership deals that alter long-term value creation unless clinical milestones materially derisk prospects.

Ongoing Losses and Negative Returns

Negative ROE and persistent net losses reflect that capital deployed has yet to generate positive returns. Declining assets suggest cash drawdown over time. Without demonstrable clinical success or revenue diversification, shareholder value remains exposed and long-term return generation is uncertain.

Revenue Volatility and Limited Visibility

Revenue is driven by lump-sum collaboration and license receipts, producing high gross margins but volatile top-line trends. This makes forecasting cash needs and operating capacity difficult, reduces predictability of sustainable revenue streams, and increases dependence on milestone-driven financing events.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of developed therapies. Additionally, the company may receive funding from grants and investments to support its research and development efforts. By focusing on advancing its proprietary iPSC technology, Century aims to establish a strong pipeline of therapies that can be licensed or commercialized, contributing to its overall revenue growth.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics shows significant revenue growth but continues to operate at a net loss with negative EBIT and EBITDA margins. The balance sheet is strong with a high equity ratio and healthy cash reserves, but cash flow is negative, indicating operational inefficiencies.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	113.34M	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	107.01M	6.59M	2.23M	5.20M	-4.58M	-1.75M
EBITDA	-14.21M	-111.47M	-121.21M	-121.20M	-89.92M	-51.44M
Net Income	-26.48M	-126.57M	-136.67M	-130.93M	-95.82M	-53.58M
Balance Sheet
Total Assets	244.72M	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	132.75M	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	44.96M	53.83M	48.17M	49.41M	25.12M	21.55M
Total Liabilities	68.37M	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	176.35M	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-112.69M	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-112.02M	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	115.75M	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	-482.00K	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 1.77 is above the 20-day moving average (MA) of 1.05, above the 50-day MA of 0.74, and above the 200-day MA of 0.59, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 88.77 is Negative, neither overbought nor oversold. The STOCH value of 93.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPSC	52 Neutral	$169.57M	-6.56	-14.23%	―	4121.12%	83.30%
LTRN	52 Neutral	$39.03M	-1.92	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CALC	51 Neutral	$84.30M	-3.36	-526.36%	―	―	-2.46%
BTAI	47 Neutral	$43.96M	-0.21	―	―	-66.96%	71.83%
ATNM	45 Neutral	$43.36M	-1.17	-133.09%	―	11.11%	20.65%
TPST	43 Neutral	$14.24M	-0.28	-405.03%	―	―	49.43%

Century Therapeutics Corporate Events

Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies

On January 12, 2026, Century Therapeutics updated an investor slide presentation detailing progress across its cell therapy pipeline and plans to unlock the value of its programs in Type 1 diabetes and autoimmune disease. The company highlighted that CNTY-813 and CNTY-308, both incorporating its Allo-Evasion 5.0 technology for enhanced immune evasion and persistence, are in IND-enabling studies with CNTY-813 targeted for an investigational filing in 2026 and early clinical data expected in 2027, while CNTY-308 is anticipated to enter the clinic in 2026. Century also reported that patient enrollment is ongoing in the Phase 1/2 CARAMEL investigator-sponsored trial of CNTY-101 in autoimmune disease, and said its cash runway extends beyond planned key clinical milestones, underscoring its capacity to advance multiple high-impact programs in parallel and strengthen its position as a leader in immune-evasive allogeneic cell therapies.

The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Announces Oversubscribed $135 Million Financing

On January 7, 2026, Century Therapeutics entered into a securities purchase agreement with institutional investors for an oversubscribed private placement expected to close on January 9, 2026, raising approximately $135 million in gross proceeds through the sale of about 117.4 million shares of common stock (or pre-funded warrants) and accompanying warrants priced in line with Nasdaq “Minimum Price” requirements. The financing, led by new investor TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, the T1D Fund and others, strengthens Century’s balance sheet to support development of its lead iPSC-derived beta islet cell therapy candidate CNTY-813 for Type 1 diabetes, including funding toward an investigational new drug filing planned for 2026 and initial clinical data expected in 2027, and could deliver an additional roughly $153 million if all warrants are exercised, while also committing the company to register the resale of the issued securities under a new registration rights agreement.

The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics announces resignation of board member

On December 18, 2025, Century Therapeutics, Inc. announced that board member Carlo Rizzuto, Ph.D., resigned from its board of directors, effective the same day. The company emphasized that Rizzuto’s departure did not arise from any disagreement over its operations, policies, or practices, and publicly expressed appreciation for his distinguished service and lasting contributions to the organization.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Updates on Cell Therapy Advancements

On December 12, 2025, Century Therapeutics updated its slide presentation to reflect advancements in its cell therapy pipeline, which will be used in investor meetings. The company is progressing with its Allo-Evasion technology, with key programs like CNTY-101 in Phase 1/2 trials for autoimmune diseases and CNTY-813 in preclinical development for Type 1 Diabetes. The announcement highlights the company’s strategic focus on executing high-impact programs and extending its cash runway beyond key clinical milestones anticipated in late 2027.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.56 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Expands Board with New Appointments

On December 9, 2025, Century Therapeutics announced the expansion of its Board of Directors from six to eight members, appointing Dr. Martin Murphy and Dr. Han Lee as new directors. Dr. Murphy, with extensive experience in life science investment and company creation, will serve on the Compensation and Nominating and Corporate Governance Committees, while Dr. Lee, with a strong background in capital formation and corporate development, will join the Audit and Compensation Committees. This strategic move is expected to enhance Century’s efforts to advance its iPSC-derived cell therapy programs, including its lead candidate CNTY-813 for type 1 diabetes, potentially delivering significant value to patients and stakeholders.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Launches Type 1 Diabetes Program

On November 13, 2025, Century Therapeutics announced the launch of its first program for Type 1 diabetes, CNTY-813, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND in 2026. The company is also advancing CNTY-308 through IND-enabling studies for B-cell-mediated diseases, targeting clinical study initiation in 2026. Additionally, Century reported a net loss of $34.4 million for the third quarter of 2025, with a cash runway estimated to extend into the fourth quarter of 2027, reflecting a strategic focus on high-impact therapeutic areas and resource allocation.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.